Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin

George G. Klee, Carol M. Preissner, Patricia G. Schryver, Robert L. Taylor, Pai C. Kao

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The immunochemiluminometric assay described uses immobilized anti-human parathyrin (parathyroid hormone, hPTH)(1-44) and anti-hPTH(44-68) antisera and acridinium ester-labeled anti-hPTH(1-34) to simultaneously measure both intact hPTH and its amino-terminal fragments. Results by the assay correlate well with those by a cAMP-based bioassay and the Nichols Allegro immunoradiometric assay. The minimal detection limit is 0.08 pmol/L. The normal range is 1.0-5.0 pmol/L, and values are higher in older women. About 90% of study patients with surgically proven parathyroid adenomas had above-normal preoperative PTH concentrations, whereas patients with hypercalcemia of malignancy had normal or suppressed values. This assay was designed to detect both intact PTH and amino-terminal PTH fragments; however, Chromatographic fractionation of pools of primary and secondary hyperparathyroid plasma showed virtually no amino-terminal fragment activity. Nonetheless, the design is important because the absence of carboxyl-terminal binding sites prevents interference by carboxyl-terminal fragments and because bioactive amino-terminal fragments will react in the assay if they are present in the patients' sera or if they are produced by in vitro proteolysis of intact PTH.

Original languageEnglish (US)
Pages (from-to)628-635
Number of pages8
JournalClinical Chemistry
Volume38
Issue number5
StatePublished - May 1992

Fingerprint

Parathyroid Hormone
Assays
Molecules
Teriparatide
Immunoradiometric Assay
Parathyroid Neoplasms
Hypercalcemia
Biological Assay
Proteolysis
Limit of Detection
Immune Sera
Esters
Reference Values
Binding Sites
Bioassay
Fractionation
Serum
Neoplasms
Plasmas

Keywords

  • Adenoma
  • Cancer
  • Hypercalcemia of malignancy

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Klee, G. G., Preissner, C. M., Schryver, P. G., Taylor, R. L., & Kao, P. C. (1992). Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin. Clinical Chemistry, 38(5), 628-635.

Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin. / Klee, George G.; Preissner, Carol M.; Schryver, Patricia G.; Taylor, Robert L.; Kao, Pai C.

In: Clinical Chemistry, Vol. 38, No. 5, 05.1992, p. 628-635.

Research output: Contribution to journalArticle

Klee, GG, Preissner, CM, Schryver, PG, Taylor, RL & Kao, PC 1992, 'Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin', Clinical Chemistry, vol. 38, no. 5, pp. 628-635.
Klee, George G. ; Preissner, Carol M. ; Schryver, Patricia G. ; Taylor, Robert L. ; Kao, Pai C. / Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin. In: Clinical Chemistry. 1992 ; Vol. 38, No. 5. pp. 628-635.
@article{3494e32286f949dbbf34512f23af4ce8,
title = "Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin",
abstract = "The immunochemiluminometric assay described uses immobilized anti-human parathyrin (parathyroid hormone, hPTH)(1-44) and anti-hPTH(44-68) antisera and acridinium ester-labeled anti-hPTH(1-34) to simultaneously measure both intact hPTH and its amino-terminal fragments. Results by the assay correlate well with those by a cAMP-based bioassay and the Nichols Allegro immunoradiometric assay. The minimal detection limit is 0.08 pmol/L. The normal range is 1.0-5.0 pmol/L, and values are higher in older women. About 90{\%} of study patients with surgically proven parathyroid adenomas had above-normal preoperative PTH concentrations, whereas patients with hypercalcemia of malignancy had normal or suppressed values. This assay was designed to detect both intact PTH and amino-terminal PTH fragments; however, Chromatographic fractionation of pools of primary and secondary hyperparathyroid plasma showed virtually no amino-terminal fragment activity. Nonetheless, the design is important because the absence of carboxyl-terminal binding sites prevents interference by carboxyl-terminal fragments and because bioactive amino-terminal fragments will react in the assay if they are present in the patients' sera or if they are produced by in vitro proteolysis of intact PTH.",
keywords = "Adenoma, Cancer, Hypercalcemia of malignancy",
author = "Klee, {George G.} and Preissner, {Carol M.} and Schryver, {Patricia G.} and Taylor, {Robert L.} and Kao, {Pai C.}",
year = "1992",
month = "5",
language = "English (US)",
volume = "38",
pages = "628--635",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "5",

}

TY - JOUR

T1 - Multisite immunochemiluminometric assay for simultaneously measuring whole-molecule and amino-terminal fragments of human parathyrin

AU - Klee, George G.

AU - Preissner, Carol M.

AU - Schryver, Patricia G.

AU - Taylor, Robert L.

AU - Kao, Pai C.

PY - 1992/5

Y1 - 1992/5

N2 - The immunochemiluminometric assay described uses immobilized anti-human parathyrin (parathyroid hormone, hPTH)(1-44) and anti-hPTH(44-68) antisera and acridinium ester-labeled anti-hPTH(1-34) to simultaneously measure both intact hPTH and its amino-terminal fragments. Results by the assay correlate well with those by a cAMP-based bioassay and the Nichols Allegro immunoradiometric assay. The minimal detection limit is 0.08 pmol/L. The normal range is 1.0-5.0 pmol/L, and values are higher in older women. About 90% of study patients with surgically proven parathyroid adenomas had above-normal preoperative PTH concentrations, whereas patients with hypercalcemia of malignancy had normal or suppressed values. This assay was designed to detect both intact PTH and amino-terminal PTH fragments; however, Chromatographic fractionation of pools of primary and secondary hyperparathyroid plasma showed virtually no amino-terminal fragment activity. Nonetheless, the design is important because the absence of carboxyl-terminal binding sites prevents interference by carboxyl-terminal fragments and because bioactive amino-terminal fragments will react in the assay if they are present in the patients' sera or if they are produced by in vitro proteolysis of intact PTH.

AB - The immunochemiluminometric assay described uses immobilized anti-human parathyrin (parathyroid hormone, hPTH)(1-44) and anti-hPTH(44-68) antisera and acridinium ester-labeled anti-hPTH(1-34) to simultaneously measure both intact hPTH and its amino-terminal fragments. Results by the assay correlate well with those by a cAMP-based bioassay and the Nichols Allegro immunoradiometric assay. The minimal detection limit is 0.08 pmol/L. The normal range is 1.0-5.0 pmol/L, and values are higher in older women. About 90% of study patients with surgically proven parathyroid adenomas had above-normal preoperative PTH concentrations, whereas patients with hypercalcemia of malignancy had normal or suppressed values. This assay was designed to detect both intact PTH and amino-terminal PTH fragments; however, Chromatographic fractionation of pools of primary and secondary hyperparathyroid plasma showed virtually no amino-terminal fragment activity. Nonetheless, the design is important because the absence of carboxyl-terminal binding sites prevents interference by carboxyl-terminal fragments and because bioactive amino-terminal fragments will react in the assay if they are present in the patients' sera or if they are produced by in vitro proteolysis of intact PTH.

KW - Adenoma

KW - Cancer

KW - Hypercalcemia of malignancy

UR - http://www.scopus.com/inward/record.url?scp=0026724773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026724773&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 628

EP - 635

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 5

ER -